Market news

Why MIUDELLA’s FDA review matters for Organon stock Organon (OGN) just picked up fresh attention after the FDA accepted a supplemental application to extend use of MIUDELLA, a copper IUD that Organon licensed globally earlier this year. The device is already indicated for pregnancy prevention for up to 3 years, with an extended duration review underway and commercial availability targeted for late 2026. For investors watching Organon stock, this product sits squarely in the women’s health...

Organon (NYSE: OGN) received FDA acceptance to review a supplemental New Drug Application for its hormone free contraceptive device MIUDELLA. The company entered an exclusive global licensing agreement for MIUDELLA, aiming to expand access to hormone free contraception across markets. Organon plans commercial availability of MIUDELLA as a longer duration contraceptive option, subject to regulatory review outcomes and launch execution. Beyond the MIUDELLA sNDA review and new global license,...

Organon (OGN) said Monday the US Food and Drug Administration has accepted for review a supplemental

JERSEY CITY, N.J., August 11, 2026--HCPs, healthcare settings and pharmacies can begin REMS certification for Organon’s hormone-free copper IUD, MIUDELLA, ahead of upcoming launch.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Organon (OGN) delivered earnings and revenue surprises of -2.30% and +1.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

JERSEY CITY, N.J., July 31, 2026--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company’s Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026.

Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

JERSEY CITY, N.J., July 24, 2026--Organon Presents VTAMA (tapinarof) cream, 1% Analysis of Phase3 Pooled Data Showing Early Consistent Improvements in Eczema Patients Across Age Groups

Shareholders of Organon & Co. (NYSE:OGN) approved the company’s proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminary voting results announced during the meeting. The special meeting was convened solely to cons

Leadership change in Canada puts Organon (OGN) in focus Organon (OGN) is back on investors’ radar after Organon Canada appointed Dominic Bégin as President and Managing Director, a leadership move that could influence how the company prioritizes its Canadian growth plans. See our latest analysis for Organon. For context, Organon’s share price is US$13.52, with a 90 day share price return of 57.21% and an 86.74% year to date share price return. The 3 year total shareholder return has declined...

Organon Canada, a global healthcare company dedicated to improving the health of women, is pleased to announce the appointment of Dominic Bégin as President and Managing Director. In this role, Mr. Bégin will lead the organization's strategic and commercial agenda, strengthen its leadership in key therapeutic areas, and expand access to cost-effective solutions, including biosimilars, for governments and payers across Canada.

JERSEY CITY, N.J., July 16, 2026--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission ("SEC"). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the second quarter 2026, which will be

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.